Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics.
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 03 Nov 2017 Results of a post-hoc analysis from NCT01527305 and NCT01051531 studies assessing the impact of once-monthly injection of paliperidone palmitate on functioning in adult patients with schizophrenia in the Asia-Pacific region, published in the Advances in Therapy
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.